Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate

MT Newswires Live

Jun 26

Neurizon Therapeutics (ASX: NUZ) said it developed a new oral liquid formulation of its drug candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, according to a Friday Australian bourse filing.

The firm said the treatment was developed in direct response to feedback from patients and carers. It is designed to support patients with all stages of the disease, particularly those with swallowing difficulties such as bulbar onset.

The firm is integrating the formulation into its ongoing clinical development program for NUZ-001, and it will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. The human bioequivalence study is scheduled to commence in the first half of 2026.

The firm's shares fell 3% on market close.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2546320583"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546320583\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546320583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546320583","market":"hk","top_or_hot":-1,"title":"Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NUZ.AU\">Neurizon Therapeutics</a> (ASX: NUZ) said it developed a new oral liquid formulation of its drug candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, according to a Friday Australian bourse filing.</p><p>The firm said the treatment was developed in direct response to feedback from patients and carers. It is designed to support patients with all stages of the disease, particularly those with swallowing difficulties such as bulbar onset.</p><p>The firm is integrating the formulation into its ongoing clinical development program for NUZ-001, and it will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. The human bioequivalence study is scheduled to commence in the first half of 2026.</p><p>The firm's shares fell 3% on market close.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-26 14:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NUZ.AU\">Neurizon Therapeutics</a> (ASX: NUZ) said it developed a new oral liquid formulation of its drug candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, according to a Friday Australian bourse filing.</p><p>The firm said the treatment was developed in direct response to feedback from patients and carers. It is designed to support patients with all stages of the disease, particularly those with swallowing difficulties such as bulbar onset.</p><p>The firm is integrating the formulation into its ongoing clinical development program for NUZ-001, and it will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. The human bioequivalence study is scheduled to commence in the first half of 2026.</p><p>The firm's shares fell 3% on market close.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2546320583","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546320583","pubTimestamp":1750919564,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurizon Therapeutics  said it developed a new oral liquid formulation of its drug candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, according to a Friday Australian bourse filing.The firm said the treatment was developed in direct response to feedback from patients and carers. It is designed to support patients with all stages of the disease, particularly those with swallowing difficulties such as bulbar onset.The firm is integrating the formulation into its ongoing clinical development program for NUZ-001, and it will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. The human bioequivalence study is scheduled to commence in the first half of 2026.The firm's shares fell 3% on market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","NUZ.AU":"NEURIZON THERAPEUTICS LTD","BK7096":"制药","BK4539":"次新股"},"translate_title":"Neurizon Therapeutics开发肌萎缩侧索硬化症候选药物口服液制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"NUZ.AU":0.9},"content_text":"Neurizon Therapeutics (ASX: NUZ) said it developed a new oral liquid formulation of its drug candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, according to a Friday Australian bourse filing.The firm said the treatment was developed in direct response to feedback from patients and carers. It is designed to support patients with all stages of the disease, particularly those with swallowing difficulties such as bulbar onset.The firm is integrating the formulation into its ongoing clinical development program for NUZ-001, and it will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. The human bioequivalence study is scheduled to commence in the first half of 2026.The firm's shares fell 3% on market close.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}